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AbstrACt
Objective International recognition of the unique needs 
of young people with cancer is growing. Many countries 
have developed specialist age-appropriate cancer services 
believing them to be of value. In England, 13 specialist 
principal treatment centres (PTCs) deliver cancer care to 
young people. Despite this expansion of specialist care, 
systematic investigation of associated outcomes and 
costs has, to date, been lacking. The aim of this paper is 
to describe recruitment and baseline characteristics of the 
BRIGHTLIGHT cohort and the development of the bespoke 
measures of levels of care and disease severity, which will 
inform the evaluation of cancer services in England.
Design Prospective, longitudinal, observational study.
setting Ninety-seven National Health Service hospitals in 
England.
Participants A total of 1114 participants were recruited and 
diagnosed between July 2012 and December 2014: 55% 
(n=618) were men, mean age was 20.1 years (SD=3.3), 
most (86%) were white and most common diagnoses were 
lymphoma (31%), germ cell tumour (19%) and leukaemia 
(13%).
results At diagnosis, median quality of life score was 
significantly lower than a published control threshold (69.7 
points); 40% had borderline to severe anxiety, and 21% 
had borderline to severe depression. There was minimal 
variation in other patient-reported outcomes according to 
age, diagnosis or severity of illness. Survival was lower in 
the cohort than for young people diagnosed during the same 
period who were not recruited (cumulative survival probability 
4 years after diagnosis: 88% vs 92%).
Conclusions Data collection was completed in March 2018. 
Longitudinal comparisons will determine outcomes and costs 
associated with access/exposure to PTCs. Findings will inform 
international intervention and policy initiatives to improve 
outcomes for young people with cancer.
IntrODuCtIOn
BRIGHTLIGHT is a programme of research 
that aims to determine whether specialist care 
for teenagers and young adults (TYA) with 
cancer is associated with improved outcomes. 
The National Institute for Health and Clinical 
Excellence (NICE) outlined in the Improving 
Outcomes Guidance for Children and Young People 
with Cancer,1 a model of specialised care based 
on a limited number of hospitals designated 
as principal treatment centres (PTCs). At that 
time, minimal information was available about 
either the constituent parts of such specialist 
care or the benefits that might accrue from it 
and why. BRIGHTLIGHT comprises six inter-
linked projects centred on a prospective, longi-
tudinal cohort of young people recruited soon 
after a diagnosis of cancer that examines their 
outcomes and experiences of cancer care. 
Additional studies address elements of special-
isation; the environment of care2 3; the compe-
tencies desirable in healthcare professionals 
delivering specialist care4; a metric to quantify 
specialist care; caregiver’s experience of care; 
and a health economic analysis to determine 
the cost of specialist care. The programme has 
been underpinned by an extensive patient and 
public involvement strategy.5–9 
Cancer in young people is uncommon, 
accounting for less than 1% of all new cancer 
diagnoses in England.10 Despite its rarity, 
strengths and limitations of this study
 ► A cohort of teenagers and young adults with newly 
diagnosed cancer was established with the involve-
ment of young people in planning and operation that 
contributed to a high rate of retention.
 ► The sociodemographic characteristics of the cohort 
are broadly similar to the contemporary teenage and 
young adult cancer population, supporting the gen-
eralisability of results.
 ► Data have been collected from multiple sources in-
cluding patients, individual clinical care records and 
established National Health Service datasets.
 ► The study recruited a smaller proportion of young 
people diagnosed with cancer in the available time 
period, resulting in lower statistical power to ad-
dress the impact of heterogeneity.
 ► A metric developed to quantify specialist care may 
not be sensitive enough to reflect the complexity of 
specialist care and individual patient pathways.
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cancer is the second leading cause of death for young 
people, accounting for 11% of deaths in those aged 
15–24 years.11 12 In addition, a number of issues argue for 
special attention for young people with cancer and for 
robust evidence to support current and future healthcare 
policies. For example, young people present with a spec-
trum of cancer types that is distinct from those affecting 
younger children and older adults.11 A cancer diagnosis 
during adolescence and young adulthood has an acute 
and unique impact on this critical and complex stage of 
life development, disrupting physical health, social and 
educational goals as well as psychological well-being.13 
These factors have additional importance when consid-
ered against the advantages that accrue to society from 
the successful treatment through the prolonged fulfil-
ment of their contribution in employment and other 
societal impacts.14
While most young people are cured, outcomes for some 
cancers have not improved in line with those achieved 
for children and older adults.15 There exists a general 
consensus among healthcare professionals that the needs 
of young people are poorly met by cancer services that are 
tailored towards the needs of children and older adults.16 
Young people fall between child and adult cancer services 
into what has been described as either ‘the grey zone’17 
or ‘no man’s land’.18 Prolonged routes to diagnosis, unfa-
vourable tumour biology with increasing age, limited 
access to clinical trials, lack of compliance with treat-
ment protocols, inconsistent use of molecular diagnostics 
that may assist with optimal care and a lack of specialist 
supportive care have all been implicated in the short fall 
in survival improvements.19–28
Young people themselves have described unsatisfactory 
experiences of care that include: lack of recognition of 
their autonomy; failure to facilitate them to meet normal 
life goals during treatment; lack of peer support; care by 
staff with little experience of young people; and finally, 
inappropriate care environments.9 29–31 The inability of 
traditional healthcare silos to meet the unique psycho-
social and healthcare needs of this specific popula-
tion is increasingly highlighted.32–34 Place of treatment 
and delivery of cancer care, in terms of both disease 
and age-appropriate specialist settings, is increasingly 
acknowledged as potentially significant to the outcomes 
for young people with cancer.35 36
To address these unique needs and deficit in outcomes’ 
knowledge, in August 2005 the NICE Improving Outcomes 
Guidance recommended that all care for patients under 
19 must be provided in age-appropriate facilities and 
those aged 19 and over should have 'unhindered access 
to age-appropriate facilities and support when needed’.1 
To accommodate this recommendation, 13 TYA PTCs 
were identified across England. Key components of the 
services of the TYA PTC encompass tumour site-specific 
expertise delivered in conjunction with meeting the 
broader psychosocial needs of young people to support 
successful navigation of critical life transitions. This is 
directed through the TYA multidisciplinary team (MDT).1 
However, despite national guidance supporting this 
approach to the delivery of cancer care for young people 
aged 15–24 years,1 around half of young people continue 
to be treated in children’s and adult cancer units with no 
or limited access to the TYA PTC, many receiving care in 
hospitals ‘designated’ by National Health Service (NHS) 
commissioners to provide elements of specialist care that 
are available in a TYA PTC.
The aim of the BRIGHTLIGHT programme of research 
is to evaluate the benefit of specialist TYA cancer services 
for young people aged 13–24 years. The study has four 
key objectives specific to the cohort:
1. Relate the proportion of care young people received 
in a TYA PTC to: quality of life, satisfaction with care, 
clinical processes and clinical outcomes.
2. Examine young people’s experience of cancer care 
through a longitudinal descriptive survey.
3. Compare social and educational milestones among 
young people receiving different levels of TYA cancer 
care.
4. Determine the costs of specialist care to young people, 
their families and the NHS.
Objectives
The aim of this paper is to describe the complex recruit-
ment process for establishing the BRIGHTLIGHT cohort, 
to provide details of bespoke measures of levels of care 
and disease severity that were developed to inform the 
analysis of the evaluation and to describe the baseline 
characteristics of the cohort.
stuDy DesIgn
The BRIGHTLIGHT cohort is a prospective longitudinal 
cohort study, obtaining data through a bespoke survey, 
administered through face-to-face interview, telephone 
interview and online, five times over 3 years: 5–7 months 
after diagnosis then at 12, 18, 24 and 36 months.37
PAtIent AnD PublIC InvOlvement
The focus of this study was identified by young people as a 
priority area for research. BRIGHTLIGHT was preceded 
by a period of feasibility work where we worked with 
young people as coresearchers to develop the research 
questions, outcome measures and study design.6 9 The 
study has a Young Advisory Panel who have worked with 
us since 2011 and who have been integral in naming the 
study,5 study management,7 8 identifying other areas for 
research38 and dissemination.39
sAmPle AnD settIng
Participants
The BRIGHTLIGHT cohort included young people aged 
13–24 years, newly diagnosed with cancer (International 
Classification of Diseases, 10th Revision codes C00–C97) 
in an English hospital and recruited within 4 months of 
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diagnosis. Eligibility criteria were as inclusive as possible 
so no restriction according to language or a sensory 
impairment that affected communication was applied. 
The only exclusion criteria were: young people receiving 
a custodial sentence; if the young person was not antic-
ipated to be alive at the first point of data collection 
(6 months after diagnosis); and recurrence of a previous 
cancer or they were not capable of completing a survey, 
for example, sedated and in intensive care.
recruitment
Young people present with a wide range of cancer diag-
noses.11 It was anticipated that to identify and recruit 
potentially eligible patients would be the biggest challenge 
because of: (1) low incidence; (2) presenting to numerous 
points in healthcare system, due to age and multiple diag-
nostic subtypes; and (3) inconsistent referral pathways 
for tertiary care. The NICE guidance was issued in 2005,1 
and by 2010, only 40% of newly diagnosed young people 
were known to a TYA MDT based at a PTC.40 Analysis of 
the national cancer datasets between 2010 and 2011 indi-
cated that young people were being treated in an addi-
tional 133 hospitals across England. Thus, to capture the 
full cohort of young people, we needed to open recruit-
ment in as many hospitals as possible, have a mechanism 
to identify young people across the country and also have 
access to an extensive network of researchers to recruit 
and administer the study questionnaires.
There were two mechanisms for identifying young 
people: first through the national cancer waiting times 
dataset, which has been reported in detail previously.41 
This is routinely collected NHS data used to monitor diag-
nostic and treatment targets; feasibility work suggested 
young people could be identified within 3 months of 
diagnosis.42 However, when this method was applied 
nationally, it was found to be neither timely nor accu-
rate so a second mechanism was introduced: principal 
investigators were asked to liaise with the coordinators 
of all tumour-specific MDTs (except prostate cancer) so 
the person managing recruitment to the study could be 
informed of new diagnoses in young people aged 13–24 
years. A third method to directly approach young people 
to invite them to participate was also introduced in the 
later stages of recruitment but did not significantly impact 
on accrual.43 
The second challenge was working with a large number of 
hospitals, of which most were likely to identify a few eligible 
patients over the course of the study and who might present 
to one of several departments. BRIGHTLIGHT opened to 
recruitment in 109 hospitals, of whom 97 identified and 
recruited between 1 and 106 (median 5) young people per 
hospital, 12 not recruiting any participants. England has 
a national network of research personnel funded by the 
National Institute for Health Research (NIHR), tasked with 
facilitating recruitment into clinical studies.41 The aim was to 
recruit 2012 young people diagnosed between July 2012 and 
December 2013. Despite making multiple targeted amend-
ments to the protocol and iteratively working with NIHR 
researchers and the TYA healthcare professional commu-
nity to increase the proportion of patients who were offered 
study entry (online supplemental file 1), recruitment was 
slower and lower than anticipated. In April 2014, an exten-
sion to recruitment until April 2015 was approved (young 
people diagnosed until December 2014, recruited within 
4 months of diagnosis), and a lower target sample size was 
agreed (figure 1).
methODs
Data were collected from three sources: young people, 
patient medical records and central NHS and Public 
Health England databases.
Data from young people
Patient-reported outcomes were collected from young 
people at five time points over 3 years: 4–7 months after 
diagnosis (wave 1), 12 months (wave 2), 18 months (wave 
3), 2 years (wave 4) and a final data capture 3 years after 
diagnosis (wave 5). Data were collected using a study-spe-
cific questionnaire, the BRIGHTLIGHT Survey37 (avail-
able under licence from https:// xip. uclb. com/ i/ 
healthcare_ tools/ brightlight_ wave1. html), which was 
administered as a face-to-face interview in young people’s 
homes at wave 1. Subsequent waves were administered 
online or through telephone interviews. At wave 1, young 
people also completed study-specific health economics 
questionnaires, described below.
The BRIGHTLIGHT Survey
The BRIGHTLIGHT Survey is an investigator and young 
person-designed self-report questionnaire that was admin-
istered through computer-assisted personal or telephone 
interview or online by an independent research organisa-
tion. It was developed using patient-experience literature44 
and was underpinned by a conceptual framework to guide 
question content.9 The BRIGHTLIGHT Survey contains 
five validated outcome measures and questions to reflect 
young people’s experience of diagnosis and cancer care 
(table 1).37 Completion of treatment occurs at different 
time points according to diagnosis. During the feasibility 
work, young people emphasised that they did not want to 
be asked questions about cancer when treatment ended 
and therefore the computer administration of the BRIGHT-
LIGHT Survey had complex routing to ensure young 
people were only asked questions that were relevant to their 
current situation.37 For example, questions related to predi-
agnosis and diagnostic experience were only asked at wave 
1. The BRIGHTLIGHT Survey also used ‘pull through’ 
options so that participants could reflect on responses given 
in previous waves before answering. For example, questions 
about employment/education goals were tailored so partic-
ipants could be asked again at wave 5 to ascertain if goals 
had changed and if this was cancer influenced.
Health economics questionnaires
Cancer/treatment-related costs incurred by young 
people and families were collected using a study-specific 
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Cost of Care Questionnaire and Cost Record. These 
included questions regarding: travel (car parking, petrol 
and capital depreciation, and public transport); time off 
work; medical equipment use; prescription and over-
the-counter drug use; cost of accommodation incurred 
through hospitalisation; complementary; and cost of 
family care for siblings. The Cost of Care Questionnaire 
was administered at wave 1 and required young people 
and their families to record costs incurred from the above 
items retrospectively since diagnosis. The Cost Record 
was given at waves 1 and 2, requesting the same informa-
tion collected prospectively on a weekly basis.
Data from medical records
Research teams who recruited young people completed 
an electronic case report form (CRF) 12 months after 
diagnosis, which contained key variables relating to diag-
nosis, treatment, clinical process and outcome variables. 
This included postcode at the time of diagnosis, locations 
of care, details of diagnosis, MDT treatment planning 
and care, and outcomes at 12 months after diagnosis. 
The Index of Multiple Deprivation (IMD) is a measure 
of socioeconomic status45 and was derived from the post-
code at diagnosis, based on the population denominator 
of England. Clinical processes of care were defined as 
documentation of:
1. Histological diagnosis.
2. Molecular diagnosis.
3. Cancer stage or prognostic group.
4. Initial treatment plan.
5. Evidence of multidisciplinary communication.
6. Assessment by supportive care services, defined as 
documented contact with a clinical nurse specialist 
plus one other member of the MDT (social worker, 
youth support coordinator, counsellor, psychologist, 
dietitian, physiotherapist and occupational thera-
pist).
7. Fertility discussion.
8. Consideration for inclusion in a clinical trial.
Figure 1 Summary of actions undertaken to improve recruitment and impact on accrual figures. (i) Open to most Trusts 
agreeing to participate (n=77); posters to advertise BRIGHTLIGHT distributed to all Trusts. (ii) Information to all newly diagnosed 
young people distributed in CLIC Sargent information packs; top recruiters reported in the TYAC weekly bulletin (Teenage 
and Young Adults with Cancer the professional organisation in the UK supporting healthcare professionals with teenagers 
and young adults with cancer). (iii) Healthcare professional information leaflets sent to all Trusts (hard copy and electronic for 
local distribution). (iv) Director/assistant directors of the National Cancer Research Network emailed all the Cancer Network 
Managers directing them to make recruitment to BRIGHTLIGHT a priority; approved amendment to allow consent to be taken at 
the same time as giving the information sheet. (v) Review of screening logs and site-specific feedback presentations sent to 
each principal treatment centre (PTC). (vi) Open to recruitment in all 13 PTCs. (vii) Approval to use social media to recruit young 
people; open in all 109 Trusts agreeing to open to recruitment. (viii) Attendance at a Teenage Cancer Trust Lead Nurse event 
to highlight recruitment issues and gain support. (ix) Emails sent by universities (communication teams or student unions) to 
current students with a link to the website to capture young people continuing with education after diagnosis; training for Youth 
Support Coordinators to be able to recruit young people. (x) Attend a CLIC Sargent Social Worker event to promote the study 
and gain support to take a recruitment role. (xi) Information on the BRIGHTLIGHT website in video format. (xii) Recruitment 
method based on the National Cancer Patient Experience Survey implemented.
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Data from national datasets
Data from National Cancer Registration and Analysis 
Service (NCRAS) and Hospital Episode Statistic (HES) 
were used to supplement and validate details of treat-
ment received in the TYA PTC, to support a detailed 
health economic evaluation based on hospital atten-
dance and healthcare received and to cross-check against 
the electronic CRF. NCRAS data included date of diag-
nosis, tumour morphology, staging and treatment data; 
and HES data included dates for admitted patient care, 
outpatient and accident and emergency attendance, plus 
receipt of chemotherapy and radiotherapy.
DevelOPment Of besPOke metrICs
Defining levels of care
BRIGHTLIGHT aims to evaluate exposure to specialist 
TYA cancer services, defined as treatment in the TYA PTC. 
In recognition that patients may receive elements of care 
in more than one hospital, we proposed that care could 
be categorised by three levels according to the propor-
tion of care received in a TYA PTC. To accurately allocate 
cohort participants to the appropriate level of care, anal-
ysis of HES data were used. In summary, PTC Trust codes 
were identified for 2012–2014 and applied to HES data 
so the proportion of days spent in a TYA PTC in the first 
6 months and 12 months after diagnosis could be calcu-
lated (details provided in online supplemental file 2).
Defining severity of illness
Advanced cancer is associated with poorer quality of 
life.46 47 We planned to compare quality of life of those 
treated in different care environments. To do so, we 
needed to consider ways to control for differences 
between patients that might influence this outcome and, 
in particular, the severity of their cancer. However, this 
is difficult for TYA as they present with a heterogeneous 
array of malignancies.11 While most cancers have staging 
Table 1 Summary of the content of the BRIGHTLIGHT Survey
Construct and questionnaire Details
Quality of life: Pediatric Quality of 
Life Questionnaire60
Contains 23 items scored on a 5-point Likert scale.
Four domains: physical, emotional, social and work/school functioning.
Two summary scores (physical and psychosocial function) and a total score.
Domain, summary and total scores on 0–100 scale, with 100 representing the best 
possible quality of life.
Scores <69.7 indicate a high risk of impaired quality of life.48
Health status: EuroQol-5 Dimension 
3 level73
Comprises five dimensions (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression) scored on three levels (no, some and severe problems).
The EQ-5D visual analogue scale records self-reported health on a vertical scale ranging 
from ‘best imaginable health state’ to worst imaginable health state’.
Scores 0–1 with 0 representing death and 1 representing perfect health (negative scores 
represent a health state worse than death).
Anxiety and depression: Hospital 
Anxiety and Depression Scale74
A measure of depression and anxiety.
Contains 14 items, scored on a four-grade scale (0–3). Summary scores for depression 
and anxiety (ranging from 0 to 21).
Scores of 8–10 are defined as borderline and 11 and over are considered moderate/
severe anxiety and depression.51
Social support: Multidimensional 
Scale of Perceived Social Support52
Scores for support by friends, family and significant others plus total support score.
Contains 12 statements, rated on 7-point Likert scale.
Total support score is an average ranging from 1 to 7; subsupport scores range 4–28.
Total scale score 1–2.9 are considered low support; a score of 3–5 is considered 
moderate support; and scores from 5.1 to 7 are considered high support.
Illness perception: The Brief Illness 
Perception Scale75
Measures the emotional and cognitive representations of illness.
Contains eight* questions with fixed response scale specific for each question, for 
example, not at all to extremely helpful.
Each question represents a different dimension of illness perception: consequence, 
personal control, treatment control, timeline, identity, coherence, emotional 
representation and concern. Responses scored 1–10, the higher the score, the greater 
perceived illness impact.
No overall score and each question represents a single domain.
Cancer experience questions37 Comprises 12 experience domains: prediagnosis experience, diagnostic experience, 
place of care, contact with healthcare professionals, treatment experience, fertility, 
involvement in clinical trials, adherence, communication and coordination of care, 
education, employment, well-being and relationships.
Total of 238 questions with question-specific responses describing experience.
*Timeline statement not included.
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criteria that differentiate between more or less extensive 
disease (typically groups 1–4 in ascending order of wors-
ening survival), stage is not directly comparable between 
cancer types, and a comparison based purely on staging 
would be meaningless due to the variation in outcomes 
between different cancers allocated to the same stage 
level. For example, stage 4 thyroid cancer is associated 
with a much higher chance of survival than, say, stage 4 
bowel cancer. Furthermore, survival alone is not a good 
indicator of severity of illness as it takes no account of 
disease and treatment morbidity both for the short and 
long term. We therefore developed a bespoke ‘severity’ 
grading system to include symptom and treatment burden 
as well as predicted survival and burden of late effects. 
Each cancer type was graded as least, intermediate and 
most severe based on cancer-specific information thus 
allowing comparisons between groups of patients with 
multiple types of cancer (table 2; detailed methodology is 
presented in online supplemental file 3).
Analysis
The number of young people at each stage of the project 
were described using a flow diagram, including the 
numbers eligible, consenting to be involved and followed 
up at each survey point. Reasons for non-participation 
at each stage were summarised. Potentially eligible 
patients who did not participate in the cohort study were 
compared against those who consented with regard to 
age, gender, ethnicity, location (based on the network 
linked to each PTC) and diagnosis. Data in both groups 
were summarised as means with SD, medians with IQRs 
or frequency and percentage (%), as appropriate and 
comparisons made using standard χ2 and t-tests. Since 
sample sizes for these comparisons were very large, statis-
tical significance is defined as p<0.001.
Survival from diagnosis was summarised using Kaplan-
Meier plots, and the cohort and non-cohort groups were 
compared using Cox regression to adjust for age, gender, 
ethnicity, location and type of cancer. Patient-reported 
outcomes collected in the first wave were scored according 
to published guidance for each of the validated measures. 
The characteristics of the cohort were summarised 
using means/medians (SD/IQR) or frequency (%) as 
appropriate.
results
A total of 1126 young people were recruited for whom 
valid consent was available from 1114 (figure 2). 
Table 2 BRIGHTLIGHT severity of illness index (see online supplemental file 3)
Cancer type11 Least severe Intermediate severity Most severe
Germ cell tumours Stages 1–3; stage unknown. Stage 4 (stage 1S=stage 4).
Leukaemias CML. ALL; other and unspecified. AML.
Non-Hodgkin’s lymphoma and 
non-specified lymphoma
Over 16 years, protocol 
unknown stage 1–2.
Over 16 s, protocol unknown; 
stage 3–4; any paediatric-type 
protocol; all unknown.
Burkitts (ICD-10 C83.7, 
morphology code 9687/3).
Hodgkin’s lymphoma All stages.
Central nervous system 
tumours
Pituitary adenomas (D35.2); 
subependymal giant cell 
astrocytoma (C43.2).
Other completely resected 
WHO grade I tumours for 
which surgery is the only 
treatment needed, except 
craniopharyngiomas.
Craniopharyngiomas; 
incompletely resected or 
unresectable grade I tumours; 
all grade II–IV tumours, 
any needing radiotherapy 
or chemotherapy. This 
includes ependymomas, 
medulloblastomas and 
intracranial GCTs.
Bone tumours Surgery only (low grade, 
periosteal and parosteal).
All other.
Soft tissue sarcoma Stages 1–2. Stage 3; unknown. Stage 4.
Rhabdomyosarcoma Low risk EpSSG A-D. All others; unknown.
Melanoma Stages 1–2 (except 2c). Stage 2c; stage 3 (except 3c); 
stage unknown.
Stage 3c; stage 4.
Carcinoma All thyroid; all stage 1; Cervix 
stage unknown.
Stages 2–3; all 
nasopharyngeal; stage 
unknown (except cervix).
Stage 4.
Miscellaneous and 
unspecified
All.
 ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; EpSSG, European Paediatric Soft Tissue 
Sarcoma Study Group; GCT, germ cell tumours; ICD-10, International Classification of Diseases, 10th Revision.
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Recruiting hospitals were required to keep a screening 
log, which was returned to the BRIGHTLIGHT team 
by 95 (87%) hospitals when recruitment ended. Of the 
2900 young people who had been screened, 429 (15%) 
were reported as not being eligible and 1877 (65%) were 
eligible to participate. No details were provided for the 
Figure 2 A summary of participation at each wave of data collection. *Drop-outs between waves due to death, permanent opt-
out or wave opt-out. Wave opt-outs prior to being issued were not permanent opt-outs; participants could opt-out of a single 
wave but participate in subsequent waves; these cases were not removed from the cohort permanently.
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remaining 594 (20%). Only 426 (23%) of those eligible 
had refused to participate, which was lower than the 
35% we had anticipated and accounted for.8 Of the 15% 
recorded as being ineligible, just over half (225, 52%) 
had either no reason recorded or appeared to have been 
deemed to be ineligible incorrectly.
Data were obtained from NCRAS for young people 
diagnosed in the same time period, who were potentially 
eligible, that is, alive 6 months after diagnosis and place of 
residence was not linked to a prison postcode. A total of 
5953 young people were diagnosed with cancer between 
July 2012 and December 2014, of whom 5835 (98%) were 
potentially eligible to participate (109 young people died 
within 6 months of diagnosis so were assumed to be too 
sick to be approached and 9 were in prison); 1114 (19%) 
appeared in the BRIGHTLIGHT cohort.
Clinical and NHS data were available for all 1114 young 
people. Of these, 830 (75%) completed the wave 1 survey 
(figure 2). In total, 163 (20%) participated once, 186 
(22%) twice, 195 (24%) completed three, 173 (21%) 
completed four and 113 (14%) took part in every wave.
Non-participants were similar in age and ethnicity 
to those in the BRIGHTLIGHT cohort, but there were 
differences in gender (a lower proportion of males 
in non-participants) and inclusion by tumour type (a 
greater proportion of young people with leukaemia 
and lymphoma, germ cell tumours and bone tumours 
compared with non-participants but lower representation 
of brain tumours, skin cancers and carcinomas) (table 3).
Of the 1114 young people in the BRIGHTLIGHT 
cohort, 618 (55%) were men, mean age at diagnosis 
was 20.13 years (SD 3.28) and 936 (86%) identified 
themselves as white. Lymphoma was the most common 
cancer type (n=350; 31%), followed by germ cell tumours 
(n=212; 19%) and leukaemia (n=145; 13%) (table 3). 
Table 4 details the sociodemographic and clinical char-
acteristics of the BRIGHTLIGHT cohort. There was an 
even distribution across socioeconomic groups. Most 
were single (n=606; 84%) and employed or in educa-
tion (n=531; 64%). Systemic anticancer therapy was the 
most common form of treatment, which was used for 880 
(79%). Thirty (3%) young people received no treatment, 
just active monitoring. The clinical processes that were 
most frequently documented in the clinical records were 
MDT communication (n=1037; 97%), cancer stage or 
prognostic group (n=1015; 94%), histology (n=974; 91%) 
and initial treatment plan (n=974; 91%). One hundred 
and sixty-seven (20%) young people reported having a 
prediagnosis long-term condition.
A total of 124 (11%) young people in the BRIGHT-
LIGHT cohort died before 31 December 2016. Results 
from Cox regression indicate that a survival benefit 
for non-BRIGHTLIGHT patients was maintained even 
after adjustment for age, gender, ethnicity and type of 
cancer; the risk of death was 34% higher for those in the 
BRIGHTLIGHT cohort compared with those not in the 
cohort (figure 3; HR estimate 1.34 [95% CIs 1.09 to 1.68], 
p=0.01; table 5). There was no evidence that survival of 
cohort participants compared with non-participants 
differed by cancer type (p value for interaction: p=0.12).
 A summary of patient-reported outcomes recorded at 
wave 1 are presented in table 6. Mean total quality of life, 
physical and emotional domain scores were <69.7 indi-
cating that, on average, young people had some impair-
ment to quality of life shortly after diagnosis.48 This is 
particularly notable in terms of physical scores where the 
average was significantly below the threshold, by more than 
10 points, for a clinically important difference.49 50 Forty 
per cent of young people could be classified as ‘cases’ for 
anxiety and 22% for depression (borderline to severe).51 
Young people reported high levels of support from friends 
(Multi-dimensional Scale of Perceived Social Support 
cut-off >5) and moderate support from family and signif-
icant others (score 3–5).52 The Brief Illness Perception 
Scale results indicate that young people felt cancer had a 
moderate effect on their life, but they perceived that treat-
ment was extremely helpful. They perceived themselves as 
having experienced a moderate number of symptoms and 
believed they had a good understanding of their cancer. 
The majority rated their satisfaction with care as being 
excellent/good (n=777; 94%). Those aged 19–24 years 
seemed to have better physical and psychosocial quality 
of life compared with those aged 13–18 years at diagnosis. 
This older age group also reported more anxiety, lower 
social support and better perceived personal control but 
lower perceived emotional representation and concerns. 
According to diagnosis, young people with a solid tumour 
had better physical scores, perceptions of consequences 
and identity but less support from friends than those with 
a blood cancer. Finally, there was a noticeable trend for 
better total quality of life, physical and psychosocial scores 
for those with less severe disease and worse emotional 
score for the intermediate severity group. Young people 
categorised by the BRIGHTLIGHT Severity of Illness 
Index as having less severe disease had better perceived 
consequences and identity  but satisfaction with care was 
highest in those with the most severe disease.
DIsCussIOn
The BRIGHTLIGHT cohort is the first national, 
prospectively recruited cohort of TYAs with cancer. 
We are able to examine in detail the complexity associ-
ated with place of care, experience and outcome. This 
is made possible through the use of linked data from 
multiple sources, so unlike other cohorts that rely solely 
on patient-reported outcomes34 47 or clinical data,32 a 
more comprehensive evaluation can be derived. Using 
national mandatory NHS datasets, we have been able 
to calculate a more robust measure of time spent 
in specialist TYA care. Other data sources, such as 
secondary analysis of the National Cancer Patient Expe-
rience data, are based on TYA PTC code at the time of 
participation,53 as such this reflects a single point in time 
and does not reflect experiences and outcomes for those 
who have exposure to both specialist and non-specialist 
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care. Measuring exposure to a TYA PTC through anal-
ysis of HES data has enabled a more objective exposure 
variable to be developed. Similarly, defining severity of 
cancer through prognosis for survival alone does not 
reflect the symptom/treatment burden of disease and 
the impact this has on quality of life during treatment 
and recovery. Systematically defining prognosis along-
side symptom and treatment burden provides a more 
Table 3 Comparison of characteristics of participants and non-participants
N BRIGHTLIGHT cohort N Non-participants P value*
Age at diagnosis (years)
  Mean (SD) 1114 20.13 (3.28) 4721 19.94 (3.33) 0.08
  Median (IQR) 20.64 (17.58, 22.95) 21 (17, 23)
Gender, n (%)
  Male 1114 618 (55) 4721 2213 (47) <0.0001
  Female 496 (45) 2508 (53)
Ethnicity n (%)
  White 1085 936 (86) 4316 3643 (84) 0.002
  Asian 82 (8) 288 (7)
  Black 22 (2) 156 (4)
  Chinese 4 (<1) 34 (<1)
  Mixed 26 (2) 74 (2)
  Other 15 (1) 121 (3)
Type of cancer, n (%)†
  Leukaemia 1114 145 (13) 4721 300 (6) <0.0001
  Lymphoma 350 (31) 781 (17)
  CNS 46 (4) 735 (16)
  Bone 102 (9) 177 (4)
  Sarcomas 78 (7) 207 (4)
  Germ cell 212 (19) 504 (11)
  Skin 45 (4) 709 (15)
  Carcinoma (not skin) 125 (11) 1210 (26)
  Miscellaneous specified 9 (<1) 55 (1)
  Unspecified malignant 2 (<1) 43 (1)
Geographical location, n (%)‡
  Birmingham 1114 155 (14) 4618 459 (10) <0.0001
  Bristol 116 (10) 351 (8)
  Cambridge 23 (2) 276 (6)
  Manchester 103 (9) 391 (8)
  Merseyside 42 (4) 239 (5)
  East Midlands 135 (12) 278 (6)
  Leeds 106 (10) 254 (6)
  Newcastle 59 (5) 305 (7)
  Oxford 19 (2) 249 (5)
  London (south) 77 (7) 668 (14)
  Sheffield 37 (3) 174 (4)
  Southampton 83 (8) 221 (5)
  London (north) 159 (14) 753 (16)
*P values from χ2 tests and t-tests as appropriate.
†Based on the Birch classification.11
‡Hospitals mapped to the multidisciplinary team at the teenage and young adult principal treatment centre they were linked to.
CNS, central nervous system.
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nuanced measure and is a better reflection of the 
severity of illness.
Selecting the study design to evaluate TYA cancer services 
across England was challenging as services were already 
in place and, in some regions of the country, long estab-
lished. There was also wide variation in implementing the 
NICE Guidance1 according to local need and pre-existing 
resources, resulting in services at PTCs not being identical. 
The decision to establish a cohort was made on the basis 
that it is suited for investigating rare exposures, allows exam-
ination of multiple outcomes for the defined exposure (to 
specialist care) and would enable us to gather data regarding 
sequence of events, with the potential to assess causality. The 
main limitation of the cohort is we only recruited a fifth of 
the population who were eligible to participate. Variation in 
diagnosis and severity between those in the cohort receiving 
different level of PTC care reduces the potential to assess 
causality.
Cohort studies are acknowledged to be challenging to 
establish and maintain, especially in rare conditions due to 
the requirement for large numbers of subjects, potential 
for selection bias and the challenges associated with subject 
retention.54–57 We anticipated that participation might favour 
those who were less unwell or had a better prognosis. The 
inclusion of significant numbers with tumours associated 
with poorer prognosis such as bone tumours and the infe-
rior survival of the cohort go against this. One of the aims of 
the BRIGHTLIGHT cohort was to evaluate socioeconomic 
Table 4 Sociodemographic and clinical characteristics of 
the BRIGHTLIGHT cohort at wave 1
Characteristic Number %
Socioeconomic status (IMD quintile) (n=1088)
  1 – most deprived 250 23
  2 194 18
  3 209 19
  4 230 21
  5 – least deprived 205 19
Marital status (n=725)
  Married/civil partnership 26 4
  Cohabiting 93 13
  Single/divorced 606 84
Current status (n=830)
  Working full/part time 257 31
  In education 274 33
  Other work (apprentice/intern/voluntary) 17 2
  Unemployed 31 4
  Long term sick 126 15
  Not seeking work 125 15
Length of inpatient stay over 12 months (n=1070) days
  Median (IQR) 25 9 to 74
Treatment (n=1114)*
  Systemic anticancer therapy 880 79
  Radiotherapy 324 29
  Surgery 551 50
  Active monitoring 30 3
  Transplant (stem cell or bone marrow) 28 3
Severity of illness (n=1114)
  Least 611 55
  Intermediate 254 23
  Most 249 22
Clinical processes of care (documentation available in clinical records)
  Histological diagnosis (n=1072) 974 91
  Molecular diagnosis (n=737)† 258 35
  Cancer stage or prognostic group (n=1078) 1015 94
  Initial treatment plan (n=1071) 974 91
  MDT communication (n=1074) 1037 97
  Assessment by supportive care services 
(n=1057)
563 53
  Fertility being discussed (n=1063) 693 65
  Consideration into a clinical trial (n=1057) 676 64
*N greater than 1114 reflects multiple treatment modalities for some 
diagnoses.
†Where relevant, indicated as not relevant in 320.
CNS, central nervous system; IMD, Index of Multiple deprivation.
Figure 3 Comparison of survival between participants in the 
cohort and non-participant.
Table 5 Comparison of survival between participants in the 
cohort and non-participants*
Estimated cumulative survival probabilities by year 
from diagnosis (95% CI)
Non-participants BRIGHTLIGHT cohort
1 year 0.98 (0.97 to 0.98) 0.98 (0.97 to 0.99)
2 years 0.95 (0.94 to 0.96) 0.92 (0.91 to 0.94)
3 years 0.93 (0.92 to 0.94) 0.89 (0.87 to 0.91)
4 years 0.92 (0.91 to 0.93) 0.88 (0.85 to 0.90)
Log rank test p value <0.0001.
*Non-participants were young people diagnosed in the 
same time frame as the BRIGHTLIGHT cohort identified 
by the National Cancer Registration and Analysis Service 
who were not part of BRIGHTLIGHT.
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variation in access to specialist care. A comparison of IMD 
quintile between those who were and were not recruited 
have enabled us to assess whether there was bias in recruit-
ment according to difference socioeconomic groups; 
however, these data were not available but warrant explo-
ration in the future. Our experience of recruitment points 
to the value of maintaining accurate screening logs and 
seeking mechanisms to complement the intelligence from 
local teams about change of status of participants such as 
death or change of address.
Our experience highlights the value of patient and 
public participation in research. We have described 
earlier in the paper the involvement young people had 
from study inception to dissemination. In total, more 
than 1200 young people have been involved in BRIGHT-
LIGHT as part of the research process, almost the same 
number as those recruited. We believe this has positively 
influenced the rates of participation, ways in which young 
people were approached and methods of data collection, 
and doubled the retention rate at wave 3.7
This population is known to have lower involvement in clin-
ical trials in comparison with children and older adults,22 58 
yet there have been no targeted interventions developed to 
improve recruitment.59 We have reported that to optimise 
recruitment to clinical trials, what we have identified as ‘the 
5 A’s’ need to be addressed, namely availability, accessibility, 
awareness, appropriateness and acceptability.58 We have 
identified factors that young people feel are acceptable for 
accessing research8 and for continuing their involvement in a 
study.7 We have also identified that the networked structures 
for facilitating recruitment into cancer research in England 
may not be optimal for the recruitment of young people.41 
The impact of not having an optimal research network was 
made apparent through BRIGHTLIGHT, as it was the first 
national study in this population. Ways to overcome this 
challenge are currently being explored by the NIHR.
A potential limitation of the BRIGHTLIGHT cohort 
study is the outcome measures that were selected to be 
included in the survey. Traditionally outcome measures 
are developed for children less than 18 years or adults 
older than 18 years. Our population crossed both age 
groups so there were limited measures validated for 
use in this population. Our measure of quality of life, 
the PedsQL, has been validated for use in adolescence 
and adulthood60 and has been used often in TYA cancer 
studies.34 61–64 The other measures, outlined in table 1, 
had no formal psychometric testing specifically in a 
TYA cancer population. However, these have been used 
extensively in studies in young people with and without 
cancer,65–71 so we are confident the results reflect a consis-
tent measure of each construct but warrants further 
exploration of the data in the future.
future PlAns
The BRIGHTLIGHT cohort was originally designed to 
evaluate short-term outcomes, from early after diagnosis 
to 3 years after diagnosis, over five time points. Data 
collection for wave 5 ended in February 2018, with results 
for the four key objectives anticipated to be available by 
the end of 2018. As noted earlier, the study has generated 
a large quantity of data, and with the recent completion 
of a James Lind Alliance Priority Setting Partnership exer-
cise for TYA exercise (http://www. ncri. org. uk/ ncri- blog/ 
top- 10- research- priorities- for- teenage- and- young- adult- 
cancer- identified/), there is the opportunity to address 
some of the unanswered questions with the BRIGHT-
LIGHT cohort. This opportunity has already been real-
ised to contribute evidence to improvements in early 
diagnosis.19 In line with NIHR guidance, patient-reported 
outcome data from the cohort will be made available to 
external researchers on acceptance of the final report in 
the NIHR Journal Library. Details of how to apply will 
be made available on the website ( www. brightlightstudy. 
com).
The philosophy of specialist TYA cancer care is to 
provide optimal cancer treatment alongside the devel-
opmentally sensitive care that enables young people to 
achieve their life goals (eg, education, employment and 
relationships) during treatment and beyond. BRIGHT-
LIGHT will evaluate this in the short-term but longer 
term follow-up may be valuable to explore whether the 
model of care delivery influences these outcomes later 
in life. We are now planning a 10-year follow-up study 
to assess the long-term impacts. We also acknowledge 
that similar to other studies quantifying care using NHS 
data,53 72 the measure of specialist care may lack discrimi-
nation, not least because it assumes that all TYA PTCs and 
other places of care are equal. Additional to the cohort, 
a case study was conducted to understand the culture of 
TYA cancer care.3 There is the potential to synthesise the 
qualitative findings from the case study with the quantita-
tive data from the cohort to develop a more detailed and 
sensitive metric to define specialist TYA cancer care. Ulti-
mately, the data generated by the cohort and BRIGHT-
LIGHT will provide new information on cancer in young 
people and determine if access to a PTC adds value. The 
relationships between specialist care and outcomes have 
previously been unclear. Findings will inform interven-
tion and policy efforts to improve outcomes for young 
people with cancer.
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